By most standards, Covidien (NYSE: COV )
has been a superior performer in the med-tech sector. That hasn't
always shown up in the company's stock performance, however, as rebound
stories like St. Jude Medical, Boston Scientific, and Bard have
raced ahead. With Covidien announcing a noisy quarter with some
apparent seasonal pressures on Friday, it looks as though Fools have an
opportunity to add shares in a high-quality name at a pretty interesting
valuation.
Continue here:
Do Disappointing Earnings Create a Good Buying Opportunity?
Showing posts with label C R Bard. Show all posts
Showing posts with label C R Bard. Show all posts
Monday, April 28, 2014
Friday, April 25, 2014
Seeking Alpha: Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard
For a company with relatively modest underlying growth trends, C.R.Bard (BCR)
has generated a fair bit of enthusiasm on the Street for the enhanced
growth prospects bought through M&A and the royalty stream from Gore.
Among the acquired products, investors are particularly keen on the
prospects for the Lutonix drug-coated balloon and management's comments
on the earnings call only seemed to add more confusion to already noisy
situation. Bard is not a particularly cheap stock at these levels and
the company is going to need better organic growth and clear
differentiation in drug-coated balloons to support further gains.
Read the full article here:
Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard
Read the full article here:
Noise Over DCBs Clouds An Otherwise Okay Quarter At Bard
Labels:
C R Bard,
Covidien,
Johnson Johnson,
Medtronic,
Seeking Alpha
Subscribe to:
Posts (Atom)